WednesdayJun 10, 2026 10:00 am

Microsoft to Have Scalable Quantum Computer by 2029

Microsoft has pulled forward its target date for building a practical quantum computer from 2033 to 2029, crediting a major jump in chip performance. Zulfi Alam, Microsoft's VP for quantum, announced the new target last week alongside the launch of Majorana 2, the follow-on to Majorana 1.  Majorana 1 was released in early 2025, and Majorana 2 builds on it as Microsoft edges toward hardware that outstrips conventional machines. A practical quantum machine would tackle classes of problems that conventional computers cannot crack within any useful timeframe.  Majorana 2 qubits hold their state for about 20 seconds, roughly 1,000 times longer than its predecessor. Keeping qubits stable is a core challenge because they are inherently fragile and easily knocked off course by their…

Continue Reading

MondayJun 08, 2026 10:00 am

Collagen Tiles Could Prevent Brain Cancer Recurrence

A clinical trial has found that placing radioactive tiles into the brain cavity at tumor removal dramatically cuts recurrence and extends survival. The ROADS trial, led by MD Anderson Cancer Center, was presented at the 2026 American Society of Clinical Oncology meeting.  It is the first randomized Phase 3 study to directly compare this approach with postoperative stereotactic radiation therapy, conducted across multiple centers. The study was sponsored by GT Medical Technologies, maker of the FDA-cleared brachytherapy device used in the trial.  Left untreated with radiation, the surgical cavity shows regrowth in 50% to 60% of patients, making some form of postoperative treatment essential. One year after…

Continue Reading

MondayJun 08, 2026 9:00 am

Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) Is ‘One to Watch’

Disseminated on behalf of Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) and may include paid advertising. Redwood AI is developing a proprietary AI platform designed to support drug discovery, synthesis planning, and chemical analysis across pharmaceutical, public safety, defense, and industrial-related markets. The company is positioned across multiple large global market opportunities, including pharmaceutical development, defense-related chemical intelligence, AI-assisted drug discovery, and CDMO infrastructure applications. Reactosphere combines synthesis planning, optimization workflows, sourcing intelligence, and chemical analysis capabilities within a single AI-driven platform. Redwood AI is advancing its AI-powered chemistry platform through research collaborations and government-supported initiatives involving organizations including UBC,…

Continue Reading

WednesdayJun 03, 2026 10:00 am

New Pill Offers Hope Against Pancreatic Cancer 

A new pill can reportedly double survival in early pancreatic cancer trials, raising cautious optimism about a disease that has long resisted treatment. Revolution Medicines' daraxonrasib targets KRAS, a gene that supplies instructions for the development of the K-Ras protein which is essentially a switch for controlling cell division, growth, and death.  Daraxonrasib belongs to a class of targeted therapies dubbed RAS inhibitors, designed to act on the KRAS gene and disrupt a genetic mutation found across multiple cancer types. The biotech company behind the novel treatment will release its full Phase 3 results at the upcoming American Society of Clinical Oncology meeting.  Pancreatic cancer has a…

Continue Reading

MondayJun 01, 2026 10:30 am

Frontieras North America Inc. Reimagines Coal for the AI Economy

The rapid rise of AI is already reshaping electricity consumption worldwide. Frontieras’ proprietary FASForm technology processes coal into multiple high-value outputs rather than using it solely for combustion. The company also focuses on infrastructure compatibility. Artificial intelligence (“AI”) is transforming the way the world uses energy. From massive data centers to advanced manufacturing systems, the technologies powering the AI boom require enormous amounts of reliable electricity, putting growing pressure on existing energy infrastructure. Frontieras North America is positioning itself within that shift through its proprietary FASForm(TM) platform, which converts coal into fuels, hydrogen and industrial products, changing one of the world’s most abundant resources…

Continue Reading

MondayJun 01, 2026 10:00 am

Limited Storage Hampers Renewable Energy in Europe

Due to the intermittent nature inherent to most sources of renewable energy, storage infrastructure will be critical to the transition to clean energy. Such facilities allow renewable energy providers to store energy produced in peak generation hours and disburse it when demand peaks. However, with Europe boasting limited energy storage infrastructure, the continent’s efforts to move away from fossil fuels effectively are being hampered. Consequently, investing in storage infrastructure could help European nations shake off their reliance on fossil fuels at a more accelerated pace. Renewable energy sources like solar and wind are capable of producing large amounts of clean…

Continue Reading

WednesdayMay 27, 2026 10:00 am

Enterprise AI Users Decry Spiraling Costs of Coding Tools

Microsoft and Uber have put a face on a problem spreading through corporate America: AI tools that work but cost much more than anyone planned. The former began phasing out its Claude Code subscriptions in mid-May, with the bulk expiring at the end of June. Uber CTO Praveen Neppalli Naga confirmed the ride-share company had burned through its entire 2026 AI budget by April, just months after Uber rolled out Claude Code to approximately 5,000 engineers. Claude Code and similar tools charge per token used, rather than a flat monthly rate, so bills scale with every task. Costs per engineer…

Continue Reading

TuesdayMay 26, 2026 10:00 am

Study Finds Many Young Adults Suffer Sexual Problems After Cancer Treatment

A new doctoral study from Sweden's Karolinska Institutet has found that sexual difficulties are common among young people who have survived cancer treatment. The nature and severity of those difficulties shift considerably based on cancer type and how intensively the patient was treated. Charlotta Bergström, a nurse and doctoral student at the Karolinska Institutet, led the research, which covered more than 1,000 patients. The study drew on Fex-Can, a research project tracking sexual and reproductive outcomes in cancer patients, with follow-up surveys over five years. Those findings were set against responses from a cancer-free peer group to establish a point…

Continue Reading

FridayMay 22, 2026 10:30 am

Frontieras North America Inc. Targets Trillion-Dollar Energy, Chemicals Markets with Transformative Processing Technology

The company’s FASForm(TM) technology produces materials already used across multiple existing segments.  What differentiates Frontieras within these sectors is the breadth of outputs generated from a single feedstock. Frontieras broke ground last month on its first commercial-scale project, which is designed to process approximately 7,500 tons of coal per day. For decades, coal's critics and coal's defenders have been arguing about the same thing: whether to burn it. Frontieras North America Inc. has a different question entirely. What happens when the industry stops burning coal and starts fractionating it? The answer, according to the company's FASForm(TM) technology, is six commercial…

Continue Reading

WednesdayMay 20, 2026 10:00 am

Researchers Create Less Toxic, More Effective Immunotherapy Against Blood Cancer 

University of North Carolina scientists have engineered immune cells that can destroy acute myeloid leukemia while sparing healthy blood tissue, overcoming a limitation that has plagued standard treatments, which have struggled to separate cancerous cells from normal cells. Immunologist Gianpietro Dotti and hematologist Paul Armistead directed research teams whose work appears in the journal Blood, offering an approach that may expand options for patients battling this deadly disease.  Acute myeloid leukemia afflicts adults and children alike, with diagnoses rising steadily, particularly across America and countries experiencing population aging. The malignancy typically advances rapidly through the bone marrow and bloodstream once it develops.  Unfortunately, existing therapies damage normal blood-forming…

Continue Reading

Contact us: (512) 354-7000